Last reviewed · How we verify
NCT06960954
PIVKA-II for Predicting Portal Vein Thrombosis in Hepatocellular Carcinoma
trial testing Prothrombin induced by vitamin K absence II (PIVKA-II) in Hepato Cellular Carcinoma (HCC) in 116 participants. Currently enrolling.
15 December 2025
Quick facts
| Lead sponsor | Tanta University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 116 |
| Start date | 15 January 2025 |
| Primary completion | 15 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Prothrombin induced by vitamin K absence II (PIVKA-II)
Conditions studied
- Hepato Cellular Carcinoma (HCC) — all drugs for Hepato Cellular Carcinoma (HCC) →
- Portal Vein Tumour Thrombosis — all drugs for Portal Vein Tumour Thrombosis →
Sponsor
Tanta University
Who can join
18 and older, any sex, with Hepato Cellular Carcinoma (HCC) or Portal Vein Tumour Thrombosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this cross-sectional observational study is to evaluate the relation between Prothrombin induced by vitamin K absence II (PIVKA-II) and the presence of portal vein tumor thrombosis (PVTT) in hepatocellular carcinoma (HCC) patients. Researchers will compare PIVKA-II serum levels in HCC patients with PVTT and without PVTT. Participants will undergo history-taking, clinical examination, laboratory investigations, PIVKA-II serum level, Child-Pugh classification, Model for End-stage Liver Disease (MELD) score, BCLC staging, abdominal ultrasonography, and Triphasic CT abdomen with contrast or MRI to evaluate tumor site, size, number, and presence of PVTT (a filling defect in the portal vein or its branch to distinguish PVTT or thrombus).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06960954
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hepato Cellular Carcinoma (HCC)
Currently open trials in the same condition.
- NCT07276100 — Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With Atezoli · Phase 2 · recruiting
- NCT06990659 — Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC) · NA · recruiting
- NCT06960863 — Fibroscan Evaluating Immunotherapy Response in Hepatocellular Carcinoma · recruiting
- NCT06812039 — HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients · Phase 2 · recruiting
- NCT06742424 — PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC · Phase 2 · recruiting
Other Tanta University trials
Trials by the same sponsor.
- NCT07398651 — Apremilast and Adalimumab in Psoriatic Arthritis Patients · NA · not yet recruiting
- NCT06966856 — This Randomized, Clinical Trial Evaluates the Efficacy of Oral Versus Sublingual Vitamin B12 Supplementation in Correcti · Phase 3 · not yet recruiting
- NCT07334197 — Effect of Melatonin on Left Ventricular Reverse Remodeling and Inflammation in Peripartum Cardiomyopathy · NA · not yet recruiting
- NCT07498998 — Glucocorticoid, Ozone and 5% Dextrose Local Injection for Pain Relief in Carpal Tunnel Syndrome · NA · not yet recruiting
- NCT07114250 — Comparative Study Between Spinal Anesthesia Versus General Anesthesia in Supine Percutaneous Nephrolithotomy Operation · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06960954 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tanta University
- Last refreshed: 7 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06960954.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing